Global Conjugate Vaccine Market - 2022-2029

Market Overview

The global conjugate vaccine market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 9.5% during the forecast period (2022-2029).

A conjugate vaccination is a subunit vaccine that uses a strong antigen as a carrier to combine a weak antigen, increasing the immune system's response to the weak antigen. Conjugate vaccines for infectious diseases are available. Some bacteria and viruses have polysaccharide coats that allow them to evade the immune system. An immature immune system can recognize these bacteria when conjugate vaccines are used because these vaccinations connect the unique polysaccharide coats to an organism by eliciting immunity and reaction. Meningococcal vaccinations to prevent meningitis, the Haemophilus influenzae type B (Hib) vaccine, and the pneumococcal vaccine are all examples of conjugate vaccines.

Market Dynamics

Growing approval for the meningococcal conjugate vaccine, increasing key players for developing and introducing vaccines for pneumococcal and meningococcal vaccines, and rising awareness about vaccination programs are the factors to drive the market in the forecast period.

The increasing FDA approvals for conjugate vaccines are expected to drive market growth.

On December 28, 2022, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine candidate (MenABCWY). Pfizer submitted MenABCWY to prevent meningococcal disease caused by the most common serogroups in individuals 10 through 25 years of age. Additionally, on October 17, 2022, GSK plc announced that the FDA had approved a new formulation of Menveo [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diptheria CRM197 Conjugate Vaccine] for individuals aged 10 to 55 years to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. The Menveo one-vial presentation is now available in a ready-to-use single vial, making it more convenient for healthcare providers. The Menveo one-vial presentation will initially be available to federal customers in the United States, with broader availability expected in mid-2023. Thus, from the above factors, the market is expected to drive in the forecast period.

Fewer side effects of the conjugate vaccine are expected to hamper the market growth.

The conjugate vaccines have had few side effects; when they have occurred, they have been mild and resolved quickly. About 10% of persons getting conjugate vaccines have common side effects such as hardening, reddening, swelling where the injection is given, malaise, moderate fever, and irritability. Other effects have been observed, but they are uncommon and disappear quickly. There is a small risk of an allergic reaction to the vaccine or one of its components, as with all medicines and vaccines. Most allergic reactions are mild (a skin rash and nothing more), but in extremely rare cases, anaphylactic shock can occur. Hence, from the above factors, the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis

The coronavirus pandemic has moderately impacted the conjugate vaccine market. MenC vaccine doses were given out in 11 Brazilian states and Northern and Southern Brazil. Reduced MenC vaccine coverage is one of the difficulties encountered during the COVID-19 pandemic, and as a result, it may raise meningococcal infection rates in Brazil. For instance, 14,832,054 doses of the meningococcal C conjugate vaccination were delivered overall during the study period, with 66.30% occurring between March 2019 and February 2020 and 33.70% between March and December 2020. The COVID-19 pandemic had a negative effect on the number of MenC vaccine doses delivered in the North and South regions (26,98% and 41.47%, respectively), as well as in the eleven Brazilian States, according to statistically significant steps that were detected.

In contrast, the global market for conjugate vaccines has grown due to the U.S. FDA's (Food and Drug Administration) expanding vaccine approvals during the pandemic. For instance, Pfizer Inc. and BioNTech S.E. announced in August 2021 that the U.S. Food and Drug Administration (FDA) had approved the Biologics License Application (BLA) for COMIRNATY (COVID-19 Vaccine, mRNA), which is intended to prevent COVID-19 in people 16 years of age and older. A thorough submission package, which included six-month efficacy and safety data after the second dose, formed the foundation for the approval. Thus, from the above factors, the market got affected and is expected to boost in the forecast period.

Segment Analysis

Multivalent Conjugate Vaccine segment is expected to hold the largest market share in conjugate vaccine market

The multivalent conjugate vaccine segment accounted for the largest market share in 2021. The multivalent immunogenic conjugates are synthesized using hydrazide chemistry to conjugate mixtures of more than one polysaccharide (at the desired ratio) to at least one carrier protein. Moreover, multivalent conjugate vaccines are cost-effective, improve manufacturing efficiency, streamline the preparation of combined conjugate vaccines, and can also be used to conjugate mixtures of other reagents (peptides, therapeutic agents) to carrier proteins to create therapeutics and reagents compared to monovalent conjugate vaccines. Therefore, it has increased the demand for multivalent conjugate vaccines. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global conjugate Vaccine market

North America region accounted for the largest market share in 2021. The rise in the prevalence of the infectious disease, the increase in the initiatives by the government, the increasing FDA approvals for the conjugate vaccine, and the rising demand for meningococcal, pneumococcal vaccines and other conjugate vaccines are the factors to drive the market in the forecast period. For instance, On April 24, 2020, the FDA approved a Biologics License Application for the MenQuadfi Meningococcal Conjugate Vaccine to prevent invasive meningococcal disease in people two years older. MenQuadfi is a quadrivalent meningococcal vaccine that uses tetanus toxoid as a protein carrier in the United States. It is available in a ready-to-use liquid formulation, eliminating the need for vaccine reconstitution for healthcare providers. Additionally, On August 31, 2022, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of the vaccines for use as single booster dose at least two months following primary or booster vaccination. Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the conjugate vaccine market are GlaxoSmithKline plc, Merck & Co. Inc., Fablife, SutroVax Inc., Sanofi Pasteur SA., Pfizer, Sinovac Biotech Ltd., IDT Biologics GmbH, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited and Bavarian Nordic.

On June 08, 2021, Pfizer Inc. announced that the FDA approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) to prevent invasive disease and pneumonia caused by the vaccine's 20 Streptococcus pneumoniae (pneumococcus) serotypes in adults 18 years and older.

GlaxoSmithKline plc:

Overview:

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat acute and chronic diseases. The Vaccines business provides vaccines for people of all ages, from babies and adolescents to adults and older people. It has a portfolio of medicines for respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty Products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Product Portfolio:

Infanrix hexa: Infanrix hexa is a vaccine used to protect babies and toddlers against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio) and diseases such as bacterial meningitis caused by the bacterium Haemophilus influenzae type b (Hib).

The global conjugate vaccine market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.